STAT3 and type 2 diabetes mellitus: Taken together, by administering the proposed multiple-molecule targeting drug, an upregulation of STAT3 and PPARγ accompanied by the downregulation of IKK, ETS1, and FAS can validly be attained, yielding encouraging results for the treatment of T2D patients.